Login
$HROW
$29.20 -$0.92 (3.05%) Live

Company Executives

Officer Age In this role Joined 2025 pay Source
Mark L. Baum Also a director
Chief Executive Officer and Chairman of the Board of Directors
53 Not stated Not stated $23,606,274
Andrew R. Boll
President, Chief Financial Officer and Corporate Secretary
43 Not stated Not stated $10,947,441
Francis W. Mullery
President and Chief Executive Officer, ImprimisRx Division
50 Since 2025
1 year
2025 $1,237,692
Amir H. Shojaei
Chief Scientific Officer
58 Since 2025
1 year
2025 $1,342,627
Patrick W. Sullivan
Chief Commercial Officer
50 Since 2026
this year
2025 Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
4
serving now
Independent
3 of 4
stated in the proxy
Average tenure
5.8 years
from year joined
CEO also chairs the board
Yes
Mark L. Baum
Director Age On board Independent Committees Other public boards 2025 pay Source
Mark L. Baum
53 2011
15 years
Not independent None stated None stated Paid as CEO
Perry J. Sternberg
57 2022
4 years
Independent
Audit Committee Compensation Committee Nomination and Corporate Governance Committee
None stated $327,514
Adrienne L. Graves
72 2024
2 years
Independent
Audit Committee Compensation Committee · Chair Nomination and Corporate Governance Committee · Chair
Ocular Therapeutix, Inc., Opus Genetics, Inc. $308,764
Lauren P. Silvernail
67 2024
2 years
Independent
Audit Committee · Chair Compensation Committee
None stated $307,514

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

4 disclosed in the proxy filed Apr 24, 2026
Perry J. Sternberg
director of the Company, currently a director of Surface
Amount not stated

Company holds 3,500,000 common shares of Surface (about 20%), accounted for under the equity method; carrying value reduced to zero.

With Surface Ophthalmics, Inc. Open in proxy
Mark L. Baum
Chief Executive Officer of the Company
Approximately $428,000
2025

Harrow's acquisition of remaining equity interests in Melt; Mr. Baum held Melt equity and received cash at closing.

With Melt Pharmaceuticals, Inc. Open in proxy
Andrew R. Boll
Chief Financial Officer of the Company
Approximately $204,000
2025

Harrow's acquisition of remaining equity interests in Melt; Mr. Boll held Melt equity and received cash at closing.

With Melt Pharmaceuticals, Inc. Open in proxy
John P. Saharek
former Chief Executive Officer of ImprimisRx; held equity interests in Melt
Approximately $10,000
2025

Harrow's acquisition of remaining equity interests in Melt; Mr. Saharek held Melt equity, received cash at closing and is entitled to contingent consideration.

With Melt Pharmaceuticals, Inc. Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support